BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

ADMA Biologics (ADMA)ADMA BiologicsCommercial

RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital

Open original release

Related news

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

ADMAADMA Biologics2026-01-12 13:00 EST

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

MDXGMiMedx2026-05-08 12:00 EST

MIMEDX Announces Launch of G4Derm® Plus

MDXGMiMedx2026-03-23 12:00 EST

MIMEDX Announces Launch of CHORIOFIX™

ALVOAlvotech2026-06-15 20:01 EST

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

ALVOAlvotech2026-06-15 20:01 EST

Alvotech efnir til útboðs á hlutabréfum í Bandaríkjunum að andvirði 125 milljónir dollara samhliða lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu

View all latest news

ADMA Biologics

ADMA Biologics is a plasma-derived biologics company focused on immunoglobulin therapies and specialty immune products. Its business is centered on plasma supply, manufacturing, and commercial execution.

Recent company news

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

ADMAADMA Biologics2026-03-27 11:00 EST

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

ADMAADMA Biologics2026-03-25 10:30 EST

ADMA Biologics Addresses Misleading Short-Seller Report

Stock data

Close
8.48 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States